Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer. The chemotherapy drugs to be used: Gemcitabine, Docetaxel, Oxaliplatin, 5-FU and alpha-interferon. The goal is to decrease the size of the tumor, so that removal by surgery can be performed. Current treatments for this stage of pancreas cancer offer less than ideal results, with little opportunity for treatment with curative intent.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benaroya Research Institute
• Collaborator: Sanofi
• Treatments: Docetaxel; Gemcitabine; Interferon-alfa-1b; Interferon-alpha; Interferons; Oxaliplatin

Criteria

Inclusion Criteria:

• Biopsy proven adenocarcinoma of the pancreas

• Tumor must be radiographically bidimensional by abdominal/pelvic CT

• Cancer must be locally advanced and not considered immediately treated by standard surgical procedure

• No prior therapy for pancreas cancer

Exclusion Criteria:

• Women who are pregnant or lactating

• Subjects who have received prior external beam radiation to the abdomen or pelvis

• Subjects receiving chronic immunosuppressive therapy (prednisone, methotrexate)